YONDELIS® (trabectedin) Patient Profiles

YONDELIS® has been studied in patients with unresectable, locally advanced, and metastatic leiomyosarcoma and liposarcoma. Read the hypothetical case studies below for more information about the appropriate use of YONDELIS® as the first choice for second-line or third-line treatment after an anthracycline-containing regimen.

Second-line treatment

A 55-year-old, postmenopausal woman with recurrent uterine leiomyosarcoma, treated with surgery followed by doxorubicin/ifosfamide.

Read more.

Advanced myxoid round cell liposarcoma of the left leg in a 58-year-old male, treated with surgical resection followed by antracycline plus ifosfamide, and radiotherapy.

Read more.

Dedifferentiated liposarcoma in the left thigh of a 34-year-old woman, treated with resection and radiotherapy, then ifosfamide/epirubicin after metastasizing to the pleural cavity and thorax.

Read more.

Third-line treatment

Recurrent uterine leiomyosarcoma in a 55-year-old woman, treated with surgery followed by gemcitabine/taxane after progression, and, following further progression, doxorubicin/ifosfamide.

Read more.

For more information about using YONDELIS® in a clinical setting, contact Janssen Medical Information Center at 800-JANSSEN (800-526-7736) or visit janssenmd.com.

You can also e-mail questions to the Janssen Medical Information Center by visiting askjanssenmedinfo.com.